Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Identifying existing, FDA-approved drugs with clinically protective effects against coronavirus disease 2019 using a big data approach

Award Number: R21LM013683
ORGANIZATION: NATIONAL LIBRARY OF MEDICINE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/20/2021
PERIOD OF PERFORMANCE END DATE: 03/31/2024

Group Awards By:

View Award Description

Identifying existing, FDA-approved drugs with clinically protective effects against coronavirus disease 2019 using a big data approach - Project Summary/Abstract Coronavirus Disease 2019 (COVID-19) is a national and global public health emergency. Because the causative virus is novel, the present options for treatment are extremely limited, and an effective vaccine could be 1-2 years away. Thus, there is an urgent need for efficacious therapeutics against the disease. While development of new drugs is under way, that process is slow and resource-intensive. In the short- to-medium term, a superior strategy is to repurpose already existing drugs to treat the disease. Over 100 drugs already approved by the Food and Drug Administration (FDA) have shown in vitro, in silico, or theoretical effect against SARS-CoV-2, the virus that causes COVID-19, or the hyperinflammatory immune response it provokes. What is unclear is how many of these have a significant, protective effect on actual patients, as only a tiny fraction of these drugs is in clinical trials. Most of these agents are chronic medications, and thus there are millions of Americans who are already using them. The first aim of this study is to assess the degree of protection any of these drugs confers against the serious complications of COVID-19 while adjusting for known risk factors and confounders. The second aim is to search for additional interactions between drugs or combinations of drugs and specific demographic and/or clinical subgroups that could be protective or harmful. The Change Healthcare Database, a part of the COVID-19 Research Database, contains up-to-date health insurance claims data for about one- third of all Americans. Using this database, this study will evaluate the impact of these drugs on the risk of four important outcomes in patients who are COVID-19-positive: need for hospitalization, use of mechanical ventilation, shock, and death. Results will be risk-adjusted for the risk factors already well established to predict poor outcomes in COVID-19. This study will further mine the data for second- and third-order interactions between drugs or combinations of drugs and different subpopulations of patients using a novel machine learning method called the Feasible Solution Algorithm (FSA). The FSA enables the researcher to uncover higher-order statistical interactions in regression models, which leads to the identification of subgroups and complexities that are not always apparent with traditional regression models. If the results show candidate drugs with highly protective effects, these can be prioritized for prospective clinical studies. Drugs that show harmful effects can be considered for discontinuation in infected or high-risk patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$7,092 )
2024	2022	CINCINNATI UNIV OF	2600 CLIFTON AVE	CINCINNATI	OH	45220	HAMILTON	USA	Medical Library Assistance	000	3	8/8/2024	NON-COMPETING CONTINUATION	-$7,092
														Subtotal = -$7,092

Issue Date FY: 2023 ( Subtotal = -$1 )
2023	2021	UNIVERSITY OF LOUISVILLE	2301 S 3RD ST	LOUISVILLE	KY	40208	JEFFERSON	USA	Medical Library Assistance	000	1	2/2/2023	NEW	-$1
														Subtotal = -$1

Issue Date FY: 2022 ( Subtotal = $196,995 )
2022	2022	UNIVERSITY OF CINCINNATI	2600 CLIFTON AVE	CINCINNATI	OH	45220	HAMILTON	USA	Medical Library Assistance	000	3	3/15/2022	NON-COMPETING CONTINUATION	$196,995
														Subtotal = $196,995

Issue Date FY: 2021 ( Subtotal = $245,840 )
2021	2021	UNIVERSITY OF CINCINNATI	2600 CLIFTON AVE	CINCINNATI	OH	45220	HAMILTON	USA	Medical Library Assistance	002	2	6/11/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$245,839
2021	2021	UNIVERSITY OF LOUISVILLE	2301 S 3RD ST	LOUISVILLE	KY	40208	JEFFERSON	USA	Medical Library Assistance	001	1	6/10/2021	NEW	-$225,170
2021	2021	UNIVERSITY OF LOUISVILLE	2301 S 3RD ST	LOUISVILLE	KY	40208	JEFFERSON	USA	Medical Library Assistance	000	1	3/31/2021	NEW	$225,171
														Subtotal = $245,840

Grand Total All Awards = $435,742

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Identifying existing, FDA-approved drugs with clinically protective effects against coronavirus disease 2019 using a big data approach

Award Number: R21LM013683

ORGANIZATION: NATIONAL LIBRARY OF MEDICINE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/20/2021

PERIOD OF PERFORMANCE END DATE: 03/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer